{"id":"https://openalex.org/W7202270454","doi":"https://doi.org/10.3389/fphar.2026.1938908","title":"Faricimab 6 mg versus aflibercept 8 mg in diabetic macular oedema: an in silico study of anchored efficacy and common-protocol treatment burden","display_name":"Faricimab 6 mg versus aflibercept 8 mg in diabetic macular oedema: an in silico study of anchored efficacy and common-protocol treatment burden","publication_year":2026,"publication_date":"2026-10-13","ids":{"openalex":"https://openalex.org/W7202270454","doi":"https://doi.org/10.3389/fphar.2026.1938908","pmid":"https://pubmed.ncbi.nlm.nih.gov/42947959","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13710820"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1938908","doi":"https://doi.org/10.3389/fphar.2026.1938908","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1938908","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938908/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938908/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042959858","display_name":"Georgios D. Panos","orcid":"https://orcid.org/0000-0001-8399-7456","observed_orcids":["https://orcid.org/0000-0001-8399-7456"]},"institutions":[{"id":"https://openalex.org/I142263535","display_name":"University of Nottingham","ror":"https://ror.org/01ee9ar58","country_code":"GB","type":"education","lineage":["https://openalex.org/I142263535"]},{"id":"https://openalex.org/I21370196","display_name":"Aristotle University of Thessaloniki","ror":"https://ror.org/02j61yw88","country_code":"GR","type":"education","lineage":["https://openalex.org/I21370196"]},{"id":"https://openalex.org/I2800980381","display_name":"AHEPA University Hospital","ror":"https://ror.org/01q1jaw52","country_code":"GR","type":"healthcare","lineage":["https://openalex.org/I2800980381"]}],"countries":["GB","GR"],"is_corresponding":true,"raw_author_name":"Georgios D. Panos","raw_affiliation_strings":["Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki","Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki","institution_ids":["https://openalex.org/I21370196","https://openalex.org/I2800980381"]},{"raw_affiliation_string":"Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham","institution_ids":["https://openalex.org/I142263535"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5042959858"],"corresponding_institution_ids":["https://openalex.org/I142263535","https://openalex.org/I21370196","https://openalex.org/I2800980381"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.61991668,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1938908","last_page":"1938908"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/faricimab","display_name":"faricimab","score":0.9470000267028809},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.9990000128746033},{"id":"https://openalex.org/keywords/diabetic-macular-edema","display_name":"diabetic macular edema","score":0.996999979019165},{"id":"https://openalex.org/keywords/treatment-burden","display_name":"treatment burden","score":0.6600000262260437},{"id":"https://openalex.org/keywords/best-corrected-visual-acuity","display_name":"best-corrected visual acuity","score":0.8849999904632568},{"id":"https://openalex.org/keywords/retinal-thickness","display_name":"retinal thickness","score":0.9869999885559082},{"id":"https://openalex.org/keywords/dosing-interval","display_name":"dosing interval","score":0.4410000145435333},{"id":"https://openalex.org/keywords/treat-and-extend-regimen","display_name":"treat-and-extend regimen","score":0.8090000152587891},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.7250000238418579},{"id":"https://openalex.org/keywords/head-to-head-comparison","display_name":"head-to-head comparison","score":0.6639999747276306},{"id":"https://openalex.org/keywords/microsimulation","display_name":"microsimulation","score":0.5180000066757202},{"id":"https://openalex.org/keywords/drug-durability","display_name":"drug durability","score":0.3059999942779541},{"id":"https://openalex.org/keywords/injection-frequency","display_name":"injection frequency","score":0.3449999988079071}],"concepts":[{"id":"https://openalex.org/C2775905019","wikidata":"https://www.wikidata.org/wiki/Q192572","display_name":"In silico","level":3,"score":0.8335000276565552},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7236999869346619},{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.48649999499320984},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38839998841285706},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.38670000433921814},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3862999975681305},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.36390000581741333},{"id":"https://openalex.org/C2779829184","wikidata":"https://www.wikidata.org/wiki/Q631361","display_name":"Diabetic retinopathy","level":3,"score":0.3513000011444092},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.3452000021934509},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.2863999903202057},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.26579999923706055},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.25040000677108765}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.3389/fphar.2026.1938908","doi":"https://doi.org/10.3389/fphar.2026.1938908","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1938908","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938908/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13710820","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710820/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13710820/pdf/fphar-17-1938908.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmid:42947959","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42947959","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:bfb4e1a89ff9416d8f311469f485eee0","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/bfb4e1a89ff9416d8f311469f485eee0","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"},{"id":"doi:10.5281/zenodo.21909868","doi":"https://doi.org/10.5281/zenodo.21909868","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.21909868","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Model"},{"id":"doi:10.5281/zenodo.21909869","doi":"https://doi.org/10.5281/zenodo.21909869","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.21909869","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Model"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1938908","doi":"https://doi.org/10.3389/fphar.2026.1938908","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1938908","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1938908/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7202270454.pdf","grobid_xml":"https://content.openalex.org/works/W7202270454.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1574902248","https://openalex.org/W2605619962","https://openalex.org/W2900925102","https://openalex.org/W4207026636","https://openalex.org/W4288448365","https://openalex.org/W4309376802","https://openalex.org/W4390341908","https://openalex.org/W4392564944","https://openalex.org/W4400589177","https://openalex.org/W4407122100","https://openalex.org/W4410431965","https://openalex.org/W4414487242","https://openalex.org/W4414822542","https://openalex.org/W4415462586","https://openalex.org/W4416137704","https://openalex.org/W7125480295","https://openalex.org/W7149402102","https://openalex.org/W7161272813","https://openalex.org/W7161294975"],"related_works":["https://openalex.org/W4410431965","https://openalex.org/W7155081699","https://openalex.org/W4414487242","https://openalex.org/W7203826178","https://openalex.org/W4390989409","https://openalex.org/W4399458878","https://openalex.org/W7165554867","https://openalex.org/W7196975728","https://openalex.org/W4406595564","https://openalex.org/W4403612883"],"abstract_inverted_index":{"Background:":[0],"No":[1],"prospective":[2],"randomised":[3],"head-to-head":[4],"trial":[5],"has":[6],"compared":[7],"faricimab":[8,118,195,220],"6":[9],"mg":[10,14,122,187,218,240,286],"with":[11,114,265],"aflibercept":[12,120,185,216],"8":[13,121,186,217,239,285],"for":[15],"diabetic":[16],"macular":[17],"oedema":[18],"(DMO).":[19],"Their":[20],"pivotal":[21],"programmes":[22],"used":[23],"materially":[24],"different":[25],"dosing":[26,82,223],"architectures,":[27],"precluding":[28],"interpretation":[29],"of":[30,45,212],"observed":[31],"interval":[32,131,171],"distributions":[33],"as":[34],"drug":[35],"properties.":[36],"Methods:":[37],"We":[38],"separated":[39],"an":[40,57],"anchored":[41],"Bayesian":[42],"aggregate-data":[43],"comparison":[44],"year-1":[46],"and":[47,53,68,98,112,136,160,174,202,231,263],"year-2":[48,170,279],"best-corrected":[49],"visual":[50],"acuity":[51],"(BCVA)":[52],"retinal-thickness":[54],"differences":[55,145,260],"from":[56],"individual-level,":[58],"discrete-time":[59],"burden":[60],"microsimulation.":[61],"The":[62,104,257],"latter":[63],"applied":[64,78],"identical":[65],"three-dose":[66],"loading":[67],"Q4W-Q16W":[69],"rules,":[70],"conditional":[71],"on":[72],"transported":[73],"durability":[74],"evidence.":[75],"Protocol":[76],"standardisation":[77],"only":[79],"to":[80,134,142,153,167,190],"burden;":[81],"history":[83],"did":[84],"not":[85],"generate":[86],"efficacy.":[87],"Inputs":[88],"represented":[89],"mixed":[90],"pivotal-trial":[91],"populations.":[92],"Structural,":[93],"prior,":[94],"composite":[95],"leave-out,":[96],"qualification":[97],"calibration":[99],"analyses":[100],"were":[101,146,261],"performed.":[102],"Results:":[103],"estimated":[105,244,258],"BCVA":[106,259],"difference":[107,253],"between":[108,254],"treatments":[109],"was":[110,123,188],"small":[111,262],"compatible":[113,264],"no":[115,252,266,282,298],"treatment":[116,267,301],"difference:":[117],"minus":[119],"+1.22":[124],"letters":[125],"at":[126,138,149,163,228,235,274],"year":[127,139,150,164,275],"1":[128,151],"(95%":[129],"uncertainty":[130],"[UI],":[132],"-0.48":[133],"+2.86)":[135],"+0.41":[137],"2":[140,165],"(-1.43":[141],"+2.27).":[143],"Retinal-thickness-reduction":[144],"+21.93":[147],"\u03bcm":[148,162],"(+1.70":[152],"+42.52;":[154],"P[\u0394":[155],">":[156],"0]":[157],"=":[158],"98.3%)":[159],"+20.53":[161],"(-1.08":[166],"+42.24);":[168],"the":[169,180,248,278,294],"included":[172,251,281,297],"zero,":[173],"estimates":[175],"varied":[176],"across":[177],"structures.":[178],"Under":[179],"common":[181],"simulated":[182,213,290],"treat-and-extend":[183],"regimen,":[184],"projected":[189],"require":[191],"fewer":[192],"injections":[193],"than":[194,219],"(7.29":[196],"vs.":[197,204,226,233],"8.01":[198],"by":[199,206],"week":[200,207,229,236],"52":[201,230],"10.93":[203],"12.60":[205],"104).":[208,237],"A":[209],"greater":[210,271],"proportion":[211],"eyes":[214],"receiving":[215],"reached":[221],"16-week":[222],"intervals":[224],"(80.2%":[225],"50.9%":[227],"77.7%":[232],"60.4%":[234],"Aflibercept":[238,284],"showed":[241,270,287],"a":[242,288],"lower":[243,289],"injection":[245,291],"burden,":[246,292],"although":[247,293],"adjusted":[249,295],"range":[250,296],"treatments.":[255],"Conclusion:":[256],"difference.":[268,283,299],"Faricimab":[269],"anatomical":[272],"improvement":[273],"1,":[276],"while":[277],"estimate":[280],"Neither":[300],"demonstrated":[302],"clinical":[303],"superiority.":[304]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-08-13T00:00:00"}